mRNA Vaccine Reduces Melanoma Death or Recurrence Risk by 42%
- Published:
- First detected:
Insights by Echo AI
A collaborative effort by Moderna and Merck has resulted in a breakthrough mRNA vaccine that, when combined with immunotherapy, reduces the risk of death or recurrence of melanoma by 42%. The vaccine, tested on over 1,100 patients, is a personalized treatment targeting unique mutations in each patient's tumor. The results, presented at the European Society of Medical Oncology conference, mark a significant advancement in melanoma treatment.
Source coverage
60
records merged
20
16 unique
5
3 unique
35
26 unique
60 Sources
Εμβόλιο mRNA μειώνει κατά 42% τον κίνδυνο θανάτου ή υποτροπής μελανώμα...
Moderna und Merck melden Durchbruch: mRNA-Krebsimpfstoff senkt Hautkre...
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk...
📖 Arte E Ideas | Vacuna de Merck/Moderna reduce más del 40% riesgo de...
Unlock Echo Intelligence
Move beyond the public feed. Monitor breaking stories across Telegram, X, and the web — with earlier visibility, clearer context, and complete control over your sources.
- Monitor Telegram, X, and web in one place
- Add any source, from niche channels to global outlets
- Build custom feeds around events, regions, entities, or keywords
- Merge duplicate coverage into one clear, source-transparent story
- Auto-translate summaries and full articles
- Search past coverage and use AI-powered editorial tools
